Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of RZ700 in Infants and Young Children
NCT07333352Phase 2Completed
- Sponsor
- Shanghai Reinovax Biologics Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in pneumococcal infection, sponsored by Shanghai Reinovax Biologics Co., Ltd.. Started Sep 2025; status: completed.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT07333352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333352.